Novel molecular targets for prevention of obesity and osteoporosis.

[1]  S. Fiorucci,et al.  FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats[S] , 2010, Journal of Lipid Research.

[2]  Jeong-Yeh Yang,et al.  Anti-obesity effects of xanthohumol plus guggulsterone in 3T3-L1 adipocytes. , 2009, Journal of medicinal food.

[3]  R. Nuti,et al.  Ospemifene use in postmenopausal women , 2009, Expert opinion on investigational drugs.

[4]  A. Tiwari,et al.  TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders. , 2009, Drug discovery today.

[5]  X. J. Sun,et al.  Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. , 2009, American journal of physiology. Endocrinology and metabolism.

[6]  Jeong-Yeh Yang,et al.  Resveratrol induces apoptosis and inhibits adipogenesis in 3T3‐L1 adipocytes , 2008, Phytotherapy research : PTR.

[7]  Hualiang Jiang,et al.  Farnesoid X Receptor Induces GLUT4 Expression Through FXR Response Element in the GLUT4 Promoter , 2008, Cellular Physiology and Biochemistry.

[8]  G. de Simone,et al.  Sibutramine: balancing weight loss benefit and possible cardiovascular risk. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[9]  Jeong-Yeh Yang,et al.  Enhanced Effects of 1,25(OH)2D3 Plus Genistein on Adipogenesis and Apoptosis in 3T3‐L1 Adipocytes , 2008, Obesity.

[10]  J. Auwerx,et al.  Bile acids and the membrane bile acid receptor TGR5--connecting nutrition and metabolism. , 2008, Thyroid : official journal of the American Thyroid Association.

[11]  B. Boyan,et al.  Enhanced effects of guggulsterone plus 1,25(OH)2D3 on 3T3-L1 adipocytes. , 2007, Biochemical and biophysical research communications.

[12]  J. Auwerx,et al.  Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. , 2007, Biochemical and biophysical research communications.

[13]  N. Arakaki,et al.  Cell‐surface H+‐ATP synthase as a potential molecular target for anti‐obesity drugs , 2007, FEBS letters.

[14]  Yunsong Liu,et al.  Is 1, 25-dihydroxyvitamin D3 an ideal substitute for dexamethasone for inducing osteogenic differentiation of human adipose tissue-derived stromal cells in vitro? , 2006, Chinese medical journal.

[15]  P. Harper,et al.  Regulating the regulator: factors that control levels and activity of the aryl hydrocarbon receptor. , 2006, Biochemical pharmacology.

[16]  H. Adlercreutz,et al.  Genistein and 17β-estradiol, but not equol, regulate vitamin D synthesis in human colon and breast cancer cells , 2006 .

[17]  J. Flier,et al.  Complex Role of the Vitamin D Receptor and Its Ligand in Adipogenesis in 3T3-L1 Cells* , 2006, Journal of Biological Chemistry.

[18]  Ke Ma,et al.  Farnesoid X receptor is essential for normal glucose homeostasis. , 2006, The Journal of clinical investigation.

[19]  Hirotoshi Nakamura,et al.  1,25-dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor. , 2006, The Journal of endocrinology.

[20]  J. Auwerx,et al.  Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.

[21]  Kunihiko Hayashi,et al.  Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1α-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss , 2005, Journal of Bone and Mineral Metabolism.

[22]  Sheue-yann Cheng,et al.  Contrasting Skeletal Phenotypes in Mice with an Identical Mutation Targeted to Thyroid Hormone Receptor α1 or β , 2005 .

[23]  J. Köhrle,et al.  Xanthohumol stimulates iodide uptake in rat thyroid-derived FRTL-5 cells. , 2005, Molecular nutrition & food research.

[24]  Richard R. Neubig,et al.  International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List , 2005, Pharmacological Reviews.

[25]  Bong-Woo Kim,et al.  Extracellular ATP is generated by ATP synthase complex in adipocyte lipid rafts , 2004, Experimental & Molecular Medicine.

[26]  Sander M Houten,et al.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.

[27]  S. Safe,et al.  Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. , 2003, Environmental health perspectives.

[28]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[29]  D. Moore,et al.  GUGULIPID: a natural cholesterol-lowering agent. , 2003, Annual review of nutrition.

[30]  N. Arakaki,et al.  Possible role of cell surface H+ -ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. , 2003, Molecular cancer research : MCR.

[31]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[32]  C. Tohyama,et al.  Modulation of oestrogen receptor signalling by association with the activated dioxin receptor , 2003, Nature.

[33]  S. Wright,et al.  Guggulsterone Is a Farnesoid X Receptor Antagonist in Coactivator Association Assays but Acts to Enhance Transcription of Bile Salt Export Pump* , 2003, The Journal of Biological Chemistry.

[34]  H. Hagiwara,et al.  3-Methylcholanthrene, which binds to the arylhydrocarbon receptor, inhibits proliferation and differentiation of osteoblasts in vitro and ossification in vivo. , 2002, Endocrinology.

[35]  K. Nakao,et al.  A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) in osteoclast formation. , 2002, Biochemical and biophysical research communications.

[36]  C. Verfaillie,et al.  Characterization of Multipotent Adult Progenitor Cells, a Subpopulation of Mesenchymal Stem Cells , 2001, Annals of the New York Academy of Sciences.

[37]  Howard C. Tenenbaum,et al.  Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. , 2000, The Journal of endocrinology.

[38]  T. A. Kerr,et al.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.

[39]  A G Leslie,et al.  The rotary mechanism of ATP synthase. , 2000, Current opinion in structural biology.

[40]  Jianbiao Zheng,et al.  Inhibition of mitochondrial proton F0F1‐ATPase/ATP synthase by polyphenolic phytochemicals , 2000, British journal of pharmacology.

[41]  T. Kanuma,et al.  Effect of 1,25(OH)2D3 on expression of estrogen receptor-alpha mRNA on rat osteosarcoma cell line (ROS 17/2.8). , 2000, Life sciences.

[42]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[43]  F. Gonzalez,et al.  Aryl-hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of commitment to adipogenesis. , 1998, Journal of cell science.

[44]  J. Corton,et al.  Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β. , 1998, Endocrinology.

[45]  Kenji Nakamura,et al.  Loss of teratogenic response to 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin (TCDD) in mice lacking the Ah (dioxin) receptor , 1997, Genes to cells : devoted to molecular & cellular mechanisms.

[46]  M. Drent,et al.  Endocrine aspects of obesity. , 1995, The Netherlands journal of medicine.

[47]  M. Noshiro,et al.  Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase. A study with the mature enzyme expressed in Escherichia coli. , 1994, European journal of biochemistry.

[48]  D. Sömjen,et al.  Modulation by vitamin D status of the responsiveness of rat bone to gonadal steroids. , 1989, Endocrinology.

[49]  O. Malhotra,et al.  Thyroid Stimulating Action of Z-Guggulsterone Obtained from Commiphora mukul , 1984, Planta medica.

[50]  B. Staels,et al.  Role of bile acids and bile acid receptors in metabolic regulation. , 2009, Physiological reviews.

[51]  Kazuhide Inoue,et al.  The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression. , 2008, Journal of pharmacological sciences.

[52]  J. Harney,et al.  Type 2 iodothyronine selenodeiodinase is expressed throughout the mouse skeleton and in the MC3T3-E1 mouse osteoblastic cell line during differentiation. , 2005, Endocrinology.

[53]  J. Hogenesch,et al.  The PAS superfamily: sensors of environmental and developmental signals. , 2000, Annual review of pharmacology and toxicology.

[54]  C. Bradfield,et al.  Ah receptor signaling pathways. , 1996, Annual review of cell and developmental biology.